ERAS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: 1) ERAS-0015's preclinical data was based on improper comparisons to Revolution Medicines, Inc. ("RevMed") and placed Erasca at risk of violating patent and trade secret protections; and (2) based on the foregoing, Defendants lacked a reasonable basis for their positive statements related to ERAS-0015.

On April 27, 2026, before the market opened, Erasca disclosed in a Form 8-K that it had received a letter from legal counsel for RevMed alleging that Erasca's ERAS-0015 infringes a RevMed patent (U.S. Patent No. 12,409,225) and is connected to alleged trade secret misappropriation, and that Erasca had "improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures."